CDE ID | CDE Description | * 421 | EDRN Participant ID (Go To: 4556) |
* 4556 | Date of contact (DD/MM/YYYY): (Go To: 2176) |
* 2176 | Visit code (Go To: 423) |
| Permissible Values (value): | Y1V06 (20) |
|
| |
| |
| |
| |
| |
* 423 | EDRN Protocol ID (Go To: 422) |
* 422 | EDRN Site ID (Go To: 929) |
* 929 | EDRN Staff ID of the person who collected the data: (Go To: 4004) |
* 4004 | Were any of the following abnormalities suspicious for mesothelioma detected? (Check all that apply) (Go To: 3028) |
| Permissible Values (value): | None (0) |
|
| |
| |
| |
| | Asymmetrical pleural thickening characterized by the presence of pleural nodularity (4) |
|
| |
| |
* 3028 | Diagnosed with study-related cancer?: (Go To: 1097) |
| Permissible Values (value): | No (0) |
|
| |
| |
| |
* 4555 | Date of diagnosis (DD/MM/YYYY): (Go To: 3107) |
* 3107 | Mesothelioma T-stage (Go To: 3105) |
| Permissible Values (value): | TX (1) |
|
| |
| |
| |
| |
| |
| |
| |
* 3105 | Mesothelioma N-stage (Go To: 3104) |
| Permissible Values (value): | NX (1) |
|
| |
| |
| |
| |
* 3104 | Mesothelioma M-stage (Go To: 3106) |
| Permissible Values (value): | MX (1) |
|
| |
| |
* 3106 | AJCC mesothelioma stage grouping: (Go To: 4005) |
| Permissible Values (value): | Stage I (2) |
|
| |
| |
| |
| |
| |
* 4005 | Is the participant able to undergo therapy for cancer? (Go To: 1097) |
| Permissible Values (value): | No (0) |
|
| |
| |
| |
1097 | Comments (do not include any participant identifiers) (Go To: End of Form) |